A phase II open-label study of ONC201 in adults with recurrent high-grade glioma

Recruiting
99 years or below
All
Phase 2
5 participants needed
1 Location

Brief description of study

This is A phase II, open-label study of ONC201 in adults with recurrent high- grade glioma. Subjects will be age 18 or older with a histone H3 K27M mutant glioma that has progressed after radiation therapy. The primary objective is to estimate the overall response rate (ORR) of ONC201 in this population. In addition, secondary objects will be to assess the safety, toxicities and tolerability of ONC201 in adults with recurrent high-grade glioma and estimate the median PFS, PFS at 2 and 6 months (progression-free survival at 6 months), median OS, and median duration of response. This study is sponsor by Oncoceutics, INC

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Medical Research
  • Age: 99 years or below
  • Gender: All
Updated on 09 Apr 2021. Study ID: 832987

Find a site

Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Message For Non Enrolling By Invitation Trial

Select a study center that’s convenient for you, and get in touch with the study team.